



RECEIVED
NOV 17 2003
TECH CENTER 1600/2900

PLEASE STAMP AND RETURN TO SHOW RECEIPT OF:

Request for Continued Examination (RCE)
In re Application of: Amy Arrow *et al.*
Application No. 09/211,794
Filed: December 15, 1998
Group Art Unit: 1635
Examiner: Mary M. Schmidt
For: Three Component Chimeric Antisense Oligonucleotides

ATTENTION: BOX RCE

Papers submitted

1. Request for Continued Examination (RCE)
2. Amendment Under 37 C.F.R. 1.114
3. Certificate Under 37 C.F.R. 3.73(b) by Oligos Etc. Inc.
4. Terminal Disclaimer executed by Roderic M.K. Dale
5. Terminal Disclaimer executed by Tod M. Woolf
6. Statement Accompanying Sequence Listing
7. Sequence Listing (1 page)
8. Computer Disk with Sequence Listing
9. Authorization to charge deposit account - \$1,570.00

Date: August 30, 2002
Attorney Docket 054800-5008-01-US
MRD/RJS:ghb



3

By 243 De 9-30-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Amy Arrow <i>et al.</i>)	
)	
Application No. 09/211,794)	Group Art Unit: 1635
)	
Filed: December 15, 1998)	Filed: Mary Schmidt
)	
For: Three Component Chimeric Antisense)	
Oligonucleotides)	

CERTIFICATE UNDER 37 C.F.R. 3.73(b)

Oligos Etc. Inc., a corporation of the state of Oregon, located at 9775 S.W. Commerce Circle, Wilsonville, Oregon 97070, certifies that it is the assignee of less than the entire right, title and interest in the patent application identified above. The extent of its ownership interest, by percentage, is fifty (50) by virtue of a chain of title from the inventors, of the patent application identified above, to the current assignee as shown below:

1. From: **Amy ARROW, Roderic M. K. DALE and Tod M. WOOLF**

To: **Oligo Therapeutics Inc. Oligos Etc. Inc. and Tod M. Woolf**

The document was recorded in the U.S. Patent and Trademark Office on December 17, 1999 at Reel 010464, Frame 0576.

2. From: **Oligo Therapeutics Inc.**

To: **Oligos Etc. Inc.**

The document was recorded in the U.S. Patent and Trademark Office on December 29, 1999 at Reel 010504, Frame 0349.

The undersigned has reviewed all the documents in the chain of title of the patent identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above. The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or

imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Oligos Etc. Inc.

Name: **Roderic M. K. Dale**
Title: **President and C.E.O.**

Signature: _____

Roderic M. K. Dale



PATENT
Attorney Docket 054800-5008-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Amy Arrow *et al.*)
)
Application No. 09/211,794) Examiner: Janet L. Epps Ford
)
Filed: December 15, 1998) Group Art Unit: 1635
)
For: Three Component Chimeric Antisense)
Oligonucleotides)

Mail Stop AF
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

RECEIVED
NOV 17 2003
TECH CENTER 1600/2900

RESPONSE TRANSMITTAL FORM


- Transmitted herewith is a Response Under 37 C.F.R. 1.116 in response to the final Office Action dated August 12, 2003 (Paper No. 28).
- Additional Papers Filed:
 - Copy of Terminal Disclaimer executed by Roderic Dale
 - Copy of Terminal Disclaimer executed by Tod M. Woolf
 - Copy of Certificate Under 37 C.F.R. 3.73(b) by Oligos Etc. Inc.
 - Copy of postcard with August 30, 2002 date stamp
- Extension of Time: The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136(a) apply. Applicants do not believe an extension of time is required. However, if Applicants have inadvertently overlooked the need for an extension of time, please consider this a Petition therefor. The Commissioner is hereby authorized to charge any additional fees which may be required, including fees due under 37 C.F.R. 1.16 and 1.17, or credit any overpayment to Deposit Account 50-0310.
- Fee Calculation (37 C.F.R. 1.16):

CLAIMS AS AMENDED						
	Remaining		Previously Paid	Extra	Rate	Total Fees
Total Claims	20	minus	20	0	\$18 each=	0.00
Independent Claims	3	minus	3	0	\$84 each=	0.00
First presentation of Multiple dependent claim					\$280.00	0.00
SUB-TOTAL =						0.00
Reduction by 1/2 for filing by a small entity						0.00
TOTAL FEE =						\$0.00

5. Constructive Petition: **Except** for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **November 12, 2003**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP


Robert Smyth
Registration No. 50,801